Effects of oral fixed-dose combinations of telmisartan plus ramipril and losartan plus ramipril in hypertension: A multicenter, prospective, randomized, double-blind, phase iii trial in adult indian patients  by Jain, S.D. et al.
VI-ILUME 66, NUMBER 6, NI-IVEMBER/DE~'EMBER 2005 
Effects of Oral Fixed-Dose Combinations of 
Telmisartan Plus Ramipril and Losartan Plus 
Ramipril in Hypertension: A Multicenter, 
Prospective, Randomized, Double-Blind, 
Phase III Trial in Adult Indian Patients 
S.D. Jain, MD1; Sangram Biradar, MD2; I. Periyandavar, MD3; 
Sanjeet Singh Sodhi, MD4; K. Anwaruddin, MDS; Ashish Gawde, MD6; 
Vidyagauri Baliga, PhD6; Kailas Gandewar, MScT; and Anish Desai, MD 6 
7Department of Medicine, Yerala Medical College, Mumbai, India; 2Mahadevappa 
Rampure Medical College, Gulbarga, Karnataka, India; 3Lifeline Diabetes Centre, 
Adyar, Chennai, India; 4Indus Hospital, Mohali, India; 5Zubeda Hospitals, Chetput, 
Chennai, India; 6Glenmark Pharmaceuticals Ltd., Mumbai, India; and 7Department 
of Preventive and Social Medicine, Lokmanya Tilak Memorial Medical College and 
Lokmanya Tilak Memorial General Hospital, Mumbai, India 
ABSTRACT 
Background: A new oral fixed-dose combination (FDC) of telmisartan plus 
ramipril is being introduced in India for the treatment of patients with stage 2 
hypertension. 
Objective: The aim of this study was to compare the effectiveness and tol- 
erability of an oral FDC of telmisartan plus ramipril with those of an oral FDC of 
losartan plus ramipril in adult Indian patients with stage 2 hypertension. 
Methods: This multicenter, prospective, randomized, ouble-blind, Phase III 
study was conducted at 5 centers in India. Indian patients aged 18 to 65 years 
with uncomplicated stage 2 essential hypertension (systolic/diastolic blood 
pressure [SBP/DBP], >160/>100 mm Hg) were enrolled. After a 2-week placebo 
run-in period, patients were randomly assigned to receive telmisartan 40 mg 
plus ramipril 5 mg (T + R) or losartan 50 mg plus ramipril 5 mg (L + R), PO 
(tablet) QD (before the morning meal) for 8 weeks. Supine blood pressure (BP) 
was measured at 0 (baseline) and 8 weeks of treatment. The primary end point 
was the mean reduction from baseline in BP. Responders were classified as 
patients who had a DBP <90 mm Hg at the end of 8 weeks of therapy. Tolerability 
was assessed using spontaneous reports of adverse events (AEs) during the 
follow-up visits and laboratory analyses performed at week 8. 
Results: A total of 289 patients were enrolled (155 men, 134 women; mean 
age, 50.74 years). Of these, 8 patients in the T + R group and 7 in the L + R group 
were lost to follow-up and considered withdrawals. At the end of week 8, the 
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mean percentage r duction in SBP was significantly greater in the T + R group 
compared with that in the L + R group (24.1% vs 19.4%; P< 0.05). The mean per- 
centage reduction in DBP was also significantly greater in the T + R group com- 
pared with that in the L + R group (17.3% vs 12.5%; P< 0.05). The response rates 
in the T + R and L + R groups were statistically similar (79.1% vs 68.7%). The 
most common AEs in the T + R and L + R groups were cough (9 [6.1%] and 11 
[7.8%] patients, respectively) and headache (7 [4.7%] and 8 [5.7%] patients, 
respectively). 
Conclusions: The results in this study in Indian patients with stage 2 essen- 
tial hypertension suggest hat the FDC of T + R controlled BP more effectively 
compared with the FDC of L + R over 8 weeks. The response rates were similar 
between the 2 groups. Both treatments were well tolerated. (Curr Ther Res Clin 
Exp. 2005;66:630-642) Copyright © 2005 Excerpta Medica, Inc. 
Key words: telmisartan, ramipril, losartan, stage 2 hypertension. 
INTRODUCTION 
The renin-angiotensin-aldosterone system (RAAS) plays an important role in 
the short- and long-term control of blood pressure (BP) through angiotensin II 
(AII). 1 A powerful vasoconstrictor, AII increases BP, promotes vascular and car- 
diac hypertrophy, and increases the risk for cardiovascular events by means 
of its effects on endothelial function and atherosclerosis. 2-5 In addition, AII 
increases the inflammatory processes in vessels and precipitates acute coro- 
nary syndromes. 6,7 Two major classes of RAAS inhibitors block the action of AII 
by different mechanisms of action. 1
Angiotensin-converting enzyme (ACE) inhibitors (eg, ramipril, perindopril) 
block the formation of AII by inhibiting its conversion from angiotensin I. They 
also prevent he degradation of bradykinin, which has important vasodilatory 
and antiproliferative effects in the vasculature. ACE inhibitors reduce the con- 
centration of AII but increase the bradykinin concentration, although the clini- 
cal importance of the latter is unclear. ACE inhibitors do not completely block 
the renin-angiotensin system because AII is produced by other non-ACE- 
mediated pathways, including chymase-mediated pathways. 1 
AII receptor blockers (ARBs), such as telmisartan and losartan, selectively 
block AII type 1 (AT1) receptors, and thus reduce the deleterious effects of AII, 
but with a reflexive increase in the AII concentration and activation of other AII 
receptor subtypes; the latter could lead to clinically important antigrowth and 
antitissue proliferation. 2,3,8 ARBs also suppress various inflammatory and athero- 
genesis markers, such as vascular cell adhesion molecules, tumor necrosis 
factor-cz, and superoxide. 7 
Telmisartan is an ARB highly selective for the AT1 receptor and has a long 
duration of action (___24 hours) and mean terminal elimination tl/2 (24 hours). In 
short-term, randomized trials, 9,1° telmisartan 80 mg QD was associated with a 
greater eduction in BP monitored by ambulatory BP monitoring during the last 
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6 hours of the dosage interval compared with losartan 50 mg or valsartan 80 mg 
QD in patients with mild to moderate hypertension. I  addition, telmisartan 80 mg 
alone and an oral fixed-dose combination (FDC) of losartan 50 mg plus hydro- 
chlorothiazide 12.5 mg have been associated with similar reductions in BP over a 
24-hour postdose interval. 11 The ARBs have been found to be equally well toler- 
ated in randomized studies. 8,12,13 
Ramipril is a prodrug rapidly hydrolyzed after absorption to form the active 
metabolite ramiprilat. Ramipril is a poor inhibitor of ACE. Ramiprilat exerts all 
known hemodynamic effects by inhibiting ACE, thereby decreasing circulating 
levels of AII and leading to a reduction in vasopressor activity and a decrease 
in peripheral vascular esistance. Ramiprilat has a long tl/2, which allows for 
once-daily administration of ramipril. Compliance has been shown to improve 
as the frequency of administration decreases. 14 
Patients with stage 2 hypertension might require 2-drug combination treat- 
ment. Initial treatment in patients with compelling high-risk indications (eg, 
type 2 diabetes mellitus, macroproteinemia, hypercholesterolemia, ischemic 
heart disease, impaired renal function) requires individualized consideration 
based on the patient's risk and/or specific condition. 14,15 Based on the results of 
clinical trials, a combination containing an ACE inhibitor and an ARB might be 
more effective clinically compared with either treatment alone. 16-21 Telmisartan 
and ramipril both have long tl/2 values and, hence, can be administered once 
daily, facilitating convenience. An FDC of telmisartan plus ramipril became 
available in India for the management of stage 2 hypertension i  2005. However, 
based on a literature search using MEDLINE (key terms: telmisartan, ramipril, 
losartan, and hypertension; years: 2003-2004), no studies have compared the 
efficacy and tolerability of this FDC with that of an FDC of losartan plus ramipril 
that is available in India. 
Thus, the aim of the present study was to compare the effectiveness and tol- 
erability of an FDC of telmisartan plus ramipril with those of an FDC of losartan 
plus ramipril in adult Indian patients with stage 2 hypertension. 
PATIENTS AND METHODS 
Study Design 
This multicenter, prospective, randomized, double-blind, comparative, 
Phase III study was undertaken in 5 centers in India. Study protocols were 
reviewed and approved by the institutional review boards of the participating in- 
stitutions. The study was conducted in compliance with the principles of Good 
Clinical Practice 22 and the Declaration of Helsinki and its amendments. 23 
Inclusion and Exclusion Criteria 
Male and female patients aged 18 to 65 years with established stage 2 uncompli- 
cated essential hypertension, defined as clinic systolic BP (SBP) 160 to 179 mm Hg 
and diastolic BP (DBP) 100 to 109 mm Hg, were enrolled in the study. 
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Pregnant (as determined using a positive serum [3-human chorionic gonado- 
tropin test and urinalysis) or breastfeeding women and patients hypersensitive 
to telmisartan, losartan, ramipril, other ACE inhibitors, and/or other ARBs were 
excluded from the study. Patients with severe hypertension, malignant hyper- 
tension, or secondary hypertension; history of acute myocardial infarction; 
coronary revascularization; and/or unstable angina pectoris and/or arrhythmia 
requiring treatment during the previous 6 months were excluded in the study. 
Patients with New York Heart Association (NYHA) 24 class IV heart failure or 
severe aortic or mitral valvular disease requiring medical treatment or causing 
hemodynamically significant disturbances; troke or transient ischemic attack 
within the previous 6 months; significant cardiac, hepatic, renal, or cerebrovas- 
cular disease; uncontrolled diabetes mellitus; and/or other serious illness were 
not included in the study. Patients with concurrent use of other hypertensives, 
including diuretics, ¢z-blockers, [3-blockers, or calcium channel blockers, and 
those with a serum potassium concentration <3.0 mEq/L and >5.0 mEq/L were 
also excluded. Patients having malignancy, severe chronic systemic diseases, 
or any condition likely to hamper compliance with the study protocol were not 
included in the study. Patients were also excluded from the study if they were 
unwilling to maintain a daily diary or had participated in a new drug study in 
the previous 3 months. 
All eligible patients were provided oral explanations about the nature of the 
study and about the study drugs. An information sheet was provided in a lan- 
guage understood by the patient, and written informed consent was obtained 
from each participant before study inclusion. 
Treatment  
All antihypertensive tr atments were discontinued, and placebo was adminis- 
tered for 2 weeks before the start of the study. Lifestyle modifications (exercise 
[light aerobic exercise for 30 minutes on most days] and diet [sodium intake 
___240 mg/d as per the Seventh Report of the Joint National Committee on Pre- 
vention, Detection, Evaluation, and Treatment of High Blood Pressure25]) were 
recommended during the 2-week placebo run-in period and continued throughout 
the study period. Compliance with lifestyle modifications was assessed using 
patient diary cards and direct questioning at each follow-up visit. 
After the placebo run-in period, patients were randomly assigned, in a 1:1 
ratio using a computer-generated randomization list, to receive an FDC of tel- 
misartan 40 mg plus ramipril 5 mg (T + R) or an FDC of losartan 50 mg plus 
ramipril 5 mg (L + R), 26'27 PO (tablet) QD (before the morning meal) for 8 weeks. 
To maintain blinding of the investigators and patients, the study drugs were 
provided in identical sealed containers. The randomization code was to be broken 
only after analyses were completed. 
No concurrent reatment for hypertension, other than the exercise and 
dietary modifications, was allowed during the study period. However, use of 
medications for concomitant conditions (eg, antidiabetic agents, acetylsalicylic 
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acid) and any other treatments that would not interfere with the study drugs 
(eg, multivitamins, antioxidants, mineral supplements) was permitted. 
After the end of the study, treatment with the FDC and/or any other antihy- 
pertensive agent at an appropriate dose was continued at the discretion of the 
attending physician. 
Efficacy Assessments 
At the screening visit (before placebo run-in), the demographic data and 
medical history of each patient was recorded, and a physical examination, 
including measurements of SBP and DBP and heart rate (HR), was performed. 
Laboratory analysis (including hematology, biochemistry, and urinalysis), 
chest radiography, and electrocardiography (ECG) also were performed at this 
visit. Follow-up visits were carried out at 2, 4, 6, and 8 weeks of treatment and 
included BP and HR measurements.  
The methods for measuring BP and HR were standardized at each center. At 
each visit, BP was measured in the morning, -24 hours after the previous drug 
administration and after 5 minutes of rest, using a standard 6-inch cuff mercury 
sphygmomanometer  (Diamond Mercurial Deluxe, IEAP, Pune, India). Patients 
were asked to sit upright in a chair with their feet on the floor and 1 arm sup- 
ported at heart level. Sitting BP was measured twice with an interval of -5 min- 
utes, and the mean of the 2 measurements was calculated. Elevated BP was con- 
firmed using the mean of 2 measurements in the other arm. HR was determined 
using palpation of the radial pulse in the wrist for 1 minute. 
Treatment compliance was monitored throughout the study using a count of 
the unused medication at each visit. 
Tolerability Assessments 
Tolerability was assessed by monitoring patients for treatment-emergent 
adverse vents (AEs), which included physical examination (including vital sign 
measurements),  laboratory analysis (including hematology, serum biochem- 
istry, and urinalysis), and ECG. AEs reported by patients or those volunteered 
by the patients in response to a question or those observed by the investigator 
at each visit were recorded on case-report forms. 
Statistical Analysis 
The pr imary efficacy end points were reduction in clinic SBP and DBP from 
baseline (week 0) to study end (week 8) and the rate of response (defined as a 
clinic DBP <90 mm Hg). 
The sample size calculation was based on the response rate and the percent- 
age of patients with a reduction in clinic SBP and DBP of at least 5 mm Hg at the 
end of treatment in each group. It was determined that 130 patients per group 
would be sufficient o detect (with 80% power and a type I error at ~ = 0.05 for 
2 comparisons) between-group differences of at least 20% in response rate and 
of 5 mm Hg in SBP and DBP. 
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All randomized patients who received _>1 dose of study medication were 
included in the intent-to-treat (ITT) analysis. Between-group differences in base- 
line demographic data, and changes in HR, laboratory parameters, and clinic 
SBP/DBP, were analyzed using analysis of variance, whereas response rate and 
the AE profile in each group were analyzed using the )~2 test. 
The per-protocol (PP) population included all patients who received at least 
1 dose of the study medication, and the PP assessment consisted primarily of 
incidences of AEs, withdrawals attributable to AEs, and serious AEs. The preva- 
lences of AEs were compared using the )~2 test. 
SPSS version 10.2 (SPSS Inc., Chicago, Illinois) was used in the statistical 
analysis. P ___ 0.05 was considered statistically significant. Data are expressed as 
mean (SD). 
RESULTS 
Patient Population 
Two hundred eighty-nine pat ients  (155 men, 134 women;  mean age, 50.74 
years) met the inclusion criteria and were enrolled in the study (T + R group, 
148 patients; L + R group, 141 patients). Of these, 15 patients (T + R group, 8 pa- 
tients; L + R group, 7 patients) were lost to follow-up; data from 274 patients 
(T + R group, 140 patients; L + R group, 134 patients) were included in the ITT 
analysis. Data from all 289 patients were included in the safety analysis. The 
demographic and clinical characteristics, including HR and SBP/DBP, at baseline 
were statistically comparable between the T + R and L + R groups (Table I). 
Table I. Demographic and baseline clinical characteristics of the study patients.* 
T+R L+R 
Characteristic (n = 148) (n = 141 ) 
Age, mean (SD), y 50.56 (10.59) 50.92 (9.98) 
Sex, no. (%) 
Male 79 (53.4) 76 (53.9) 
Female 69 (46.6) 65 (46.1) 
Weight, mean (SD), kg 59.33 (10.85) 58.82 (10.42) 
Comorbidities, no. (%) 
Type 2 diabetes mellitus 19 (12.8) 16 (11.3) 
CHD 2 (1.4) 3 (2.1) 
Peripheral vascular disease 1 (0.7) 2 (1.4) 
History of MI/stroke 1 (0.7) 1 (0.7) 
Other t 8 (5.4) 1 0 (7.1) 
T + R = telmisartan plus ramipril; L + R = Iosartan plus ramipril; CHD = coronary heart disease; MI = myo- 
cardial infarction. 
*No significant between-group differences were found. 
tlncludes rheumatoid arthritis and osteoarthritis. 
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Effectiveness 
Changes in SBP 
At weeks 4, 6, and 8, the mean (SD) SBP values were significantly reduced 
from baseline in the 2 treatment groups (T + R: 157.07 [9.32], 149.19 [10.02], and 
131.78 [11.36] mm Hg, respectively, vs 173.62 [11.06] mm Hg; L + R: 160.41 [10.72], 
152.28 [10.61], and 141.17 [11.70] mm Hg, respectively, vs 175.13 [10.67] mm Hg; 
all, P < 0.05). The percentage reductions from baseline in SBP were statistically 
similar between the 2 groups at 4 and 6 weeks (T + R, 9.5% and 14.1%, respec- 
tively; L + R, 8.5% and 13.0%, respectively), but were different at the end of week 
8 (24.1% and 19.4% in the T + R and L + R groups, respectively [P< 0.05 between 
groups]) (Table it). 
Changes in DBP 
At weeks 4, 6, and 8, the mean (SD) DBP values were significantly reduced 
from baseline in the 2 treatment groups (T + R: 95.52 [7.14], 92.34 [6.50], and 
87.54 [7.10] mm Hg, respectively, vs 105.91 [7.26] mm Hg; L + R: 97.75 [6.99], 
94.83 [6.88], and 93.08 [7.49] mm Hg, respectively, vs 106.42 [6.78] mm Hg; all, 
P< 0.05). The percentage reductions from baseline in DBP were statistically sim- 
ilar between the 2 groups at 4 and 6 weeks (T + R, 9.8% and 12.8%, respectively; 
L + R, 8.1% and 10.9%, respectively). At the end of week 8, there was a 17.3% 
reduction in the mean DBP in the T + R group, which was significantly greater 
compared with the reduction of 12.5% observed in the L + R group (P < 0.05 
between groups) (Table it). 
Response 
A total of 111 (79.3%) patients receiving T + R reached a DBP of <90 mm Hg, 
which was statistically similar to the 92 (68.7%) rate in the L + R group (Table iii). 
Table II. Blood pressure (BP) (ram Hg) over 8 weeks of t reatment  w i th  telmisartan 
plus ramipri l  (T + R) or Iosartan plus ramipri l  (L + R) in patients w i th  stage 
2 essential hypertension.* Values are mean (SD). 
SBP DBP 
T+R L+R T+R L+R 
Study Week (n = 140) (n = 134) (n = 140) (n = 134) 
0 (Baseline) 173.62 (11.06) 175.13 (10.67) 105.91 (7.26) 106.42 (6.78) 
2 169.88 (10.44) 171.27 (10.24) 103.45 (7.13) 103.84 (7.45) 
4 157.07 (9.32) t 160.41 (10.72) t 95.52 (7.14) t 97.75 (6.99) t 
6 149.19 (I0.02) t 152.28 (I0.61) t 92.34 (6.50) t 94.83 (6.88) t 
8 131.78 (I 1.36) t 141 .I 7 (I 1.70) t 87.54 (7.1 O) t 93.08 (7.49) t 
SBP = systolic BP; DBP = diastolic BP. 
*Eight and 7 patients were withdrawn from the 
follow-up. 
tp < 0.05 versus baseline. 
T + R and L + R groups, respectively, due to loss to 
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Table III. Response* after 8 weeks of t reatment with telmisartan plus ramipril 
(T + R) or Iosartan plus ramipril (L + R) in patients with uncompli- 
cated stage 2 essential hypertension. T~ Values are no. (%) of patients. 
T+R L+R 
DBP, mm Hg (n = 140) (n = 134) 
___90 111 (z9.3) 02 (68#) 
91-95 24 (17.1) 34 (25.4) 
96-I 00 3 (2.1) 6 (4.5) 
>1 O0 2 (1.4) 2 (1.5) 
DBP = diastolic blood pressure. 
*Response was defined as a clinic DBP <90 mm Hg. 
tNo significant between-group differences were found. 
~Eight and 7 patients were withdrawn from the T + R and L + R groups, respectively, due to 
loss to follow-up. 
Tolerability 
Table IV shows the AEs in the 2 treatment groups. Twenty-two (14.9%) patients 
in the T + R group experienced AEs compared with 23 (16.3%) patients in the L + R 
group; this difference between the 2 groups was not statistically significant. The 
most common AEs were cough (9 [6.1%] and 11 [7.8%], respectively) and head- 
ache (7 [4.7%] and 8 [5.7%], respectively), followed by dizziness (2 [1.4%] and 
4 [2.8%], respectively), diarrhea (4 [2.7%] and 1 [0.7%], respectively), and upper 
respiratory tract infection (eg, sinusitis, pharyngitis) (5 [3.4%] and 4 [2.8%], 
respectively). Most of the AEs were mild to moderate in severity. Cough was 
severe in 3 patients (T + R, 1 patient; L + R, 2 patients). None of the patients dis- 
continued ue to an AE. 
No statistically significant changes in the HR were found at follow-up visits 
with either treatment. Laboratory investigations, uch as hematology, did not 
show any significant changes from baseline. Other investigations, uch as serum 
biochemistry and blood glucose concentration measurement, did not show any 
significant changes from baseline. At baseline, the mean (SD) concentrat ions of
serum potassium were 4.24 (0.35) mEq/L in the T + R group and 4.21 (0.28) mEq/L 
in the L + R group. At the end of the s tudy  period, no signif icant changes in 
the mean (SD) potass ium concentrat ions  were found, and the values were 
4.21 (0.28) and 4.24 (0.25) mEq/L in the T + R and L + R groups, respectively. 
At baseline, mean (SD) serum creatinine concentrat ions were 0.92 (0.21) and 
0.91 (0.23) mg/dL in the T + R and L + R groups, respectively. After treatment, 
no significant changes from baseline concentrat ions were found (0.90 [0.14] and 
0.87 [0.13] mg/dL in the T + R and L + R groups, respectively). 
DISCUSSION 
Hypertension is one of the most common disorders een in clinical practice and 
is associated with major clinical, public health, and economic consequences.  
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Although well-tolerated and effective antihypertensive drugs are widely avail- 
able and evidence for the benefits of BP control is compelling, in most hyper- 
tensive patients worldwide, BP remains uncontrol led with monotherapy. 28 Com- 
bination therapy provides better control of BP in a greater number  of patients 
compared with monotherapy.  27 The advantages of an FDC are that it provides 
better control of BP by targeting >1 pathophysiologic mechanism, improves 
the tolerabil ity of individual components  of the preparation, confers cardio- 
vascular protect ion through modification of the risk factors by the individual 
components,  and improves compliance as a result of a reduction in the number 
of tablets to be consumed. 29'3° 
This study found that both of the FDCs (T + R and L + R) were efficacious in 
reducing BP. However, the combination of T + R seemed more effective com- 
pared with that of L + R: at the end of 8 weeks of treatment, he reductions in 
SBP and DBP were greater with T + R compared with those with L + R (24.1% 
and 17.3%, respectively, vs 19.4% and 12.5%, respectively; both, P < 0.05). How- 
ever, the number of patients achieving the target of <90 mm Hg was statis- 
tically similar between the 2 groups (79.1% and 68.6% in the T + R and L + R 
groups, respectively). Based on the literature search, no studies comparing 
these 2 combinations have been published. 
A combination of low doses of enalapril (5 mg) and losartan (50 mg) adminis- 
tered twice weekly was reported to be more effective in normalizing BP compared 
with enalapril 10 mg in patients with moderate hypertension. 31 In a 12-week, mul- 
ticenter trial in 315 Indian hypertensive patients with DM, the combination of L + 
R 50/5 mg QD was found to be effective not only in reducing BP (at 12 weeks: SBP, 
by 21.0%; DBP, by 19.3%; both, P< 0.05 vs baseline) but also in reducing microal- 
buminuria, with 20.8% of patients achieving normoalbuminuria. 32 
The synergistic actions of the combination of an ACE inhibitor and an ARB 
can be considered useful in achieving optimal BP control and reducing cardio- 
vascular isk. 
In general, drugs that are intrinsically long acting are preferred for the treat- 
ment of hypertension because hypertension requires persistent, rather than 
intermittent, BP control. 33 Compliance is thought to improve with once-daily 
administration28'34: a long-acting effect minimizes variation in BP lowering over a 
24-hour dosing interval and beyond, minimizing the risks of missed doses.  28,34,35 
The better  BP control  (SBP, -24.1%; DBP, -17.3%) achieved with T + R might 
be related to the longer tl/2 of telmisartan (24 hours) and trough-peak ratio 
(>80%). 9,28 
In the present study, no significant changes in HR were found throughout the 
study period. Similar results were reported in a small, randomized, double-blind 
study by Murdoch et al, 36 in which arterial pressure was decreased without an 
increase in HR when an ARB (eprosartan 400-800 mg/d) was added to a regimen 
containing an ACE inhibitor in 18 patients with stable NYHA 24 class II to IV con- 
gestive heart failure. Similar low rates of AEs were found in the T + R and 
L + R groups. None of the AEs were severe or resulted in s tudy  withdrawal.  
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In a double-blind study in 223 patients with mild to moderate  hypertension,  1° a 
larger proport ion of patients (8.8%) receiving losartan 50 mg/d discontinued 
t reatment  due to an AE compared with those receiving telmisartan 40 mg QD 
(1.8%), or 80 mg QD (0), or p lacebo (1.8%). 
The present study had some limitations. It was undertaken in a restr icted 
group of patients due to several  exclusion criteria, preventing extrapolat ion of 
the results to the general population. Furthermore,  the study was undertaken 
for a short  duration. A long-term follow-up study of the 2 FDCs is warranted.  
CONCLUSIONS 
The results in this &week study in Indian patients with stage 2 essential hy- 
pertension suggest hat the FDC of T + R was more efficacious in reducing SBP 
and DBP compared with the FDC of L + R. The percentages of responders  in the 
2 groups were statistically similar. Both t reatments  were well tolerated. 
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